Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options
- PMID: 30205192
- DOI: 10.1016/j.micpath.2018.09.014
Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options
Abstract
Candida auris emerged as a pathogen resistant to multiple antifungal and has been associated with nosocomial outbreaks with high transmission capacity between hospitalized individuals. C. auris was first described in 2009, after being isolated from the external ear canal discharge of a patient in Japan. The difficulty in identification, incorrect use of antifungal drugs, and treatment failure are causes of high mortality. Since then, C. auris has been increasingly reported from East Asia to North America, with substantial fatalities and misidentification. This review aims at describing the epidemiology, virulence, risk factors, resistance, and therapeutic options in C. auris infections.
Keywords: Candida auris; Resistance; Virulence factor.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Candida auris: an Emerging Fungal Pathogen.J Clin Microbiol. 2018 Jan 24;56(2):e01588-17. doi: 10.1128/JCM.01588-17. Print 2018 Feb. J Clin Microbiol. 2018. PMID: 29167291 Free PMC article. Review.
-
Candida auris-the growing menace to global health.Mycoses. 2019 Aug;62(8):620-637. doi: 10.1111/myc.12904. Epub 2019 Jun 18. Mycoses. 2019. PMID: 30773703 Review.
-
Candida auris: a worrisome, globally emerging pathogen.Expert Rev Anti Infect Ther. 2017 Sep;15(9):819-827. doi: 10.1080/14787210.2017.1364992. Epub 2017 Aug 14. Expert Rev Anti Infect Ther. 2017. PMID: 28783385 Review.
-
Candida auris and Nosocomial Infection.Curr Drug Targets. 2020;21(4):365-373. doi: 10.2174/1389450120666190924155631. Curr Drug Targets. 2020. PMID: 31549952 Review.
-
Candida auris: The recent emergence of a multidrug-resistant fungal pathogen.Med Mycol. 2019 Jan 1;57(1):1-12. doi: 10.1093/mmy/myy054. Med Mycol. 2019. PMID: 30085270 Review.
Cited by
-
Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections.Pathogens. 2023 Feb 10;12(2):293. doi: 10.3390/pathogens12020293. Pathogens. 2023. PMID: 36839565 Free PMC article. Review.
-
Risk Factors for Candidozyma auris Among Admitted Patients in Riyadh, Saudi Arabia (2020-2022).Infect Drug Resist. 2025 Jul 8;18:3369-3381. doi: 10.2147/IDR.S528127. eCollection 2025. Infect Drug Resist. 2025. PMID: 40657277 Free PMC article.
-
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Crit Care. 2023 Nov 20;27(1):449. doi: 10.1186/s13054-023-04742-w. Crit Care. 2023. PMID: 37981676 Free PMC article. Review.
-
In vitro antifungal activity of Cinnamomum zeylanicum bark and leaf essential oils against Candida albicans and Candida auris.Appl Microbiol Biotechnol. 2020 Oct;104(20):8911-8924. doi: 10.1007/s00253-020-10829-z. Epub 2020 Sep 3. Appl Microbiol Biotechnol. 2020. PMID: 32880694 Free PMC article.
-
ClaID: a Rapid Method of Clade-Level Identification of the Multidrug Resistant Human Fungal Pathogen Candida auris.Microbiol Spectr. 2022 Apr 27;10(2):e0063422. doi: 10.1128/spectrum.00634-22. Epub 2022 Mar 28. Microbiol Spectr. 2022. PMID: 35343775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical